Xenetic Biosciences Files 8-K on Security Holder Vote

TL;DR

Xenetic Biosciences is having a shareholder vote, details to follow.

AI Summary

On December 11, 2024, Xenetic Biosciences, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify the nature of the vote or any outcomes.

Why It Matters

This filing indicates that Xenetic Biosciences is seeking approval from its shareholders on certain matters, which could impact the company's future direction or corporate governance.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.

Key Players & Entities

• Xenetic Biosciences, Inc. (company) — Registrant
• December 11, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-37937 (identifier) — SEC File Number
• 45-2952962 (identifier) — IRS Employer Identification No.
• 945 Concord Street, Framingham, Massachusetts 01701 (address) — Principal executive offices
• (781) 778-7720 (phone_number) — Business phone

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq

Filing Documents

• xenetic_8k.htm (8-K) — 38KB
• 0001683168-24-008712.txt ( ) — 232KB
• xbio-20241211.xsd (EX-101.SCH) — 3KB
• xbio-20241211_lab.xml (EX-101.LAB) — 33KB
• xbio-20241211_pre.xml (EX-101.PRE) — 22KB
• xbio-20241211_def.xml (EX-101.DEF) — 26KB
• xenetic_8k_htm.xml (XML) — 3KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 11, 2024, Xenetic Biosciences, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders of the Company voted on the following four proposals and cast their votes as described below. 1. The Company's stockholders approved the election of the following six nominees with each director receiving votes as follows: Name For Withheld Broker Non-Votes Dr. Grigory Borisenko 486,395 18,588 391,780 Mr. Firdaus Jal Dastoor 470,826 34,157 391,780 Dr. Dmitry Genkin 483,081 21,902 391,780 Dr. Roger Kornberg 458,022 46,961 391,780 Mr. Moshe Mizrahy 482,135 22,848 391,780 Mr. Alexey Vinogradov 485,179 19,804 391,780 2. The Company's stockholders voted upon and approved the ratification of the selection of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. The votes on this proposal were as follows: For Against Abstained Broker Non-Votes 878,207 15,137 3,419 - 3. The Company's stockholders voted upon and approved, on a non-binding, advisory basis, the Company's named executive officer compensation. The votes on this proposal were as follows: For Against Abstained Broker Non-Votes 462,285 40,600 2,098 391,780 4. The Company's stockholders voted upon and approved, on a non-binding, advisory basis, the frequency of holding future votes regarding named executive officer compensation ("Say on Frequency") every 1 year. The votes on this proposal were as follows: 1 Year 2 Years 3 Years Abstained Broker Non-Votes 470,918 3,600 3,631 26,834 391,780 Consistent with the recommendation of the Company's Board of Directors, as set forth in the 2024 Proxy Statement, and based on the results of this non-binding advisory vote, it is the Company's intent that fu

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENETIC BIOSCIENCES, INC. By: /s/ James Parslow Date: December 13, 2024 Name: James Parslow Title: Interim Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR